Bendamustine vs. fludarabine/cyclophosphamide lymphodepletion prior to BCMA CAR-T cell therapy in multiple myeloma - Top-Institutions - MDSpire

Bendamustine vs. fludarabine/cyclophosphamide lymphodepletion prior to BCMA CAR-T cell therapy in multiple myeloma

  • By

  • Surbhi Sidana

  • Hitomi Hosoya

  • Alexandria Jensen

  • Lawrence Liu

  • Anmol Goyal

  • Vanna Hovanky

  • Bita Sahaf

  • Sushma Bharadwaj

  • Theresa Latchford

  • Sally Arai

  • Sheryl Leahy

  • Matthew Mei

  • Lihua E. Budde

  • Lori S. Muffly

  • Matthew J. Frank

  • Saurabh Dahiya

  • Myo Htut

  • David Miklos

  • Murali Janakiram

  • October 13, 2023

  • 0 min

Share

Top Institutions in Hematology

Brief introduction explaining scope and methodology.

  • #1

    Stanford University
    Stanford University

    Stanford, CA

    Key Differentiators

    • Hematology
    • Oncology
    • Cellular Therapy
    • Immunotherapy

  • #2

    City of Hope National Medical Center
    City of Hope National Medical Center

    Duarte, CA

    Key Differentiators

    • Hematology
    • Oncology
    • Cellular Therapy

  • #3

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Hematology
    • Oncology
    • Cellular Therapy
    • Immunotherapy

  • #4

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Hematology
    • Oncology
    • Cellular Therapy

  • #5

    National Cancer Institute (NCI)
    National Cancer Institute (NCI)

    Bethesda, MD

    Key Differentiators

    • Hematology
    • Oncology
    • Cellular Therapy
    • Immunotherapy

Original Source(s)

Bendamustine vs. fludarabine/cyclophosphamide lymphodepletion prior to BCMA CAR-T cell therapy in multiple myeloma

  • by Surbhi Sidana, Hitomi Hosoya, Alexandria Jensen, Lawrence Liu, Anmol Goyal, Vanna Hovanky, Bita Sahaf, Sushma Bharadwaj, Theresa Latchford, Sally Arai, Sheryl Leahy, Matthew Mei, Lihua E. Budde, Lori S. Muffly, Matthew J. Frank, Saurabh Dahiya, Myo Htut, David Miklos, Murali Janakiram

  • October 13, 2023

Related Content

Infection risk associated with teclistamab in relapsed/refractory multiple myeloma: a systematic review and meta-analysis of clinical trial and real-world evidence

Dietary patterns among individuals with plasma cell disorders– opportunities for targeted interventions

Optimisation of patient-reported outcome measurement for haematological cancer patients receiving novel immunotherapies: perspectives of multi-stakeholders